Iceland· IS-EU/1/09/602/001-002

Scintimun

A 99mtc-technetium-antigranulozyten antikörper product containing besilesomabum inn, registered in Iceland by Telix Innovations. The same ATC class is registered in 9 of our 19 countries.

ATC V09HA03

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedScintimunATCV09HA03REGISTER NO.IS-EU/1/09/602/001-002PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

99mtc-technetium-antigranulozyten antikörper is registered in 9 of 19 countries.

Countries holding a registration under ATC V09HA03 (99mtc-technetium-antigranulozyten antikörper), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 6 of them publish a price we can compare per daily dose

99mtc-technetium-antigranulozyten antikörper · ATC V09HA03

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Besilesomabum INN
Manufacturer
Telix Innovations
Country
Iceland (IS)
ATC code
V09HA03
ATC class
99mTc-Technetium-Antigranulozyten Antikörper
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/598528f9-4064-4196-95cd-599fb861c022
GET /v1/drugs/598528f9-4064-4196-95cd-599fb861c022?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Samstæða fyrir geislavirkt lyf",
  "source": "lyfjastofnun",
  "atc_raw": "V09HA03",
  "marketed": false,
  "strength": "1 mg",
  "ma_number": "EU/1/09/602/001-002",
  "substance": "Besilesomabum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "40199"
}

See everything about 99mtc-technetium-antigranulozyten antikörper.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.